Ophthalmic Pharmacology Practice Questions

Q: A patient with glaucoma is being treated with systemic beta blockers. Which of the following medications should be avoided?

Levobunolol. **Explanation:** The core concept tested here is the **additive effect and systemic safety** of beta-blockers. **Why Levobunolol is the correct answer:** Levobunolol is a potent, non-selective **topical beta-blocker**. When a patient is already on systemic beta-blockers (e.g., for hypertension or ischemic heart disease), adding topical beta-blockers can lead to significant systemic absorption through the nasolacrimal duct. This results in an "additive effect," increasing the risk of severe adverse reactions such as **bradycardia, heart block, and bronchospasm**. Furthermore, the intraocular pressure (IOP) lowering effect of topical beta-blockers is significantly reduced in patients already taking systemic versions due to receptor saturation. **Analysis of Incorrect Options:** * **A. Brimonidine:** This is an alpha-2 agonist. It lowers IOP by decreasing aqueous production and increasing uveoscleral outflow. It does not share the same systemic contraindications as beta-blockers. * **B. Dorzolamide:** A topical carbonic anhydrase inhibitor. It reduces aqueous secretion and is a safe alternative for patients who cannot tolerate beta-blockers. * **D. Prostaglandin Analogues (e.g., Latanoprost):** These are the first-line treatment for primary open-angle glaucoma. They work by increasing uveoscleral outflow and have no significant systemic interaction with beta-blockers. **Clinical Pearls for NEET-PG:** * **Betaxolol** is a cardioselective ($\beta_1$) blocker and is relatively safer in patients with mild pulmonary issues, though still used with caution. * To minimize systemic absorption of any eye drop, advise patients to perform **punctal occlusion** (pressing the inner corner of the eye) for 2–3 minutes after instillation. * **Timolol** is the most commonly used topical beta-blocker but is contraindicated in patients with asthma or 2nd/3rd-degree heart block.

Q: Which of the following statements is NOT true regarding atropine?

Fast acting. **Explanation:** Atropine is a potent, non-selective muscarinic antagonist. The correct answer is **C (Fast acting)** because Atropine is actually the **longest-acting** cycloplegic and mydriatic available. It takes approximately 30–60 minutes to achieve maximal effect, and its recovery period can last up to **7–14 days**. In contrast, drugs like Tropicamide are preferred for rapid action (20–30 minutes). **Analysis of Options:** * **A. Used as an eye ointment:** True. In children, Atropine is preferred as a 1% ointment rather than drops to minimize systemic absorption through the nasolacrimal duct, reducing the risk of systemic toxicity (e.g., flushing, fever, tachycardia). * **B. Used in refraction in children < 5 years:** True. Atropine is the "Gold Standard" for cycloplegic refraction in children under 5 (and those with accommodative esotropia) because they have a very strong ciliary muscle that requires a potent agent for complete paralysis. * **D. Experimentally used in myopia:** True. Low-dose Atropine (0.01%) is clinically used to slow the progression of myopia in children by preventing axial elongation of the eyeball. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Blocks M3 receptors in the sphincter pupillae (causing mydriasis) and the ciliary muscle (causing cycloplegia). * **Drug of Choice:** For **Iridocyclitis** (to prevent posterior synechiae and provide pain relief by resting the ciliary muscle). * **Contraindication:** Absolute contraindication in **Primary Angle Closure Glaucoma (PACG)**. * **Antidote:** Physostigmine is used for atropine poisoning.

Q: Which of the following clinical trials is used to measure the response of a drug in non-infectious uveitis?

Luminate. **Explanation:** The **Luminate trial** (specifically the Luminate study program) evaluated the efficacy and safety of **Intravitreal Fluocinolone Acetonide (YUTIQ)** in patients with chronic, non-infectious uveitis affecting the posterior segment. This trial was pivotal in demonstrating that a sustained-release corticosteroid implant could significantly reduce the rate of uveitis recurrence and improve visual acuity over a 36-month period. **Analysis of Incorrect Options:** * **CATT (Comparison of Age-related Macular Degeneration Treatments Trials):** A landmark study that compared the efficacy of **Ranibizumab** (Lucentis) vs. **Bevacizumab** (Avastin) for the treatment of neovascular (wet) AMD. It concluded that both drugs were highly effective and had similar outcomes. * **ETDRS (Early Treatment Diabetic Retinopathy Study):** This trial established the gold standard for managing diabetic retinopathy. It defined "Clinically Significant Macular Edema" (CSME) and validated the use of **laser photocoagulation** and aspirin in diabetic patients. * **AREDS (Age-Related Eye Disease Study):** This trial evaluated the effect of high-dose **antioxidant vitamins and minerals** (Vitamin C, E, Beta-carotene, Zinc) on the progression of AMD and cataracts. (Note: AREDS2 later replaced Beta-carotene with Lutein/Zeaxanthin). **High-Yield Clinical Pearls for NEET-PG:** * **Non-infectious uveitis** is primarily managed with corticosteroids (topical, periocular, or intravitreal implants like Ozurdex or Retisert/Yutiq). * **MUST KNOW Trials:** * **SCORE:** Steroids vs. Laser for RVO. * **DRCR.net:** Various protocols for Diabetic Macular Edema (DME). * **HORIZON/ANCHOR:** Ranibizumab for AMD.

Q: Which agent is used for pupillary dilatation in children?

Atropine. **Explanation:** The correct answer is **Atropine (Option A)**. In pediatric ophthalmology, the primary goal for pupillary dilatation is often to perform an accurate **cycloplegic refraction**. Children have a very strong accommodative reflex due to a highly active ciliary muscle. Atropine is the most potent cycloplegic and mydriatic agent available. It effectively paralyzes the ciliary muscle (cycloplegia) and dilates the pupil (mydriasis), allowing for the measurement of the full refractive error, especially in cases of accommodative esotropia and pediatric strabismus. **Analysis of Options:** * **Homatropine (Option B):** It is a semi-synthetic alkaloid with moderate potency. While used for cycloplegia, its effect is weaker than Atropine and is more commonly used in treating anterior uveitis to prevent synechiae. * **Tropicamide (Option C):** It has the fastest onset and shortest duration of action. It is the drug of choice for routine fundus examination in **adults**, but its cycloplegic effect is insufficient to overcome the strong accommodation in children. * **Phenylephrine (Option D):** This is a sympathomimetic alpha-1 agonist. It causes mydriasis without cycloplegia. It is often used as an adjunct to tropicamide but is never used alone for refraction in children. **High-Yield NEET-PG Pearls:** * **Drug of Choice (DOC):** Atropine (1% ointment or drops) is the DOC for refraction in children **<7 years** of age. * **Cyclopentolate:** The DOC for children **7–24 years** of age. * **Atropine Toxicity:** Watch for "Red as a beet, Dry as a bone, Blind as a bat, Mad as a hatter." In children, use ointment to prevent systemic absorption via the nasolacrimal duct. * **Duration:** Atropine effects can last up to 7–10 days.

Q: Which drug is known to cause bull's eye maculopathy?

Chloroquine. **Explanation:** **Chloroquine** (and its derivative Hydroxychloroquine) is the classic cause of **Bull’s Eye Maculopathy**. These drugs have a high affinity for melanin and bind to the **Retinal Pigment Epithelium (RPE)**. Chronic accumulation leads to RPE atrophy in a concentric ring around the fovea, sparing the central foveal area initially. This creates the characteristic "bull's eye" appearance on fundoscopy. It is a dose-dependent toxicity; the risk increases significantly when the cumulative dose of Chloroquine exceeds 460g or Hydroxychloroquine exceeds 5mg/kg/day. **Analysis of Incorrect Options:** * **Phenytoin:** Primarily associated with neuro-ophthalmic side effects such as **nystagmus** (most common), diplopia, and ophthalmoplegia, rather than maculopathy. * **Steroids:** The hallmark ocular side effects of systemic or topical steroids are **Posterior Subcapsular Cataract (PSC)** and **Secondary Open Angle Glaucoma** (due to increased resistance to aqueous outflow). * **Ethambutol:** This antitubercular drug is notorious for causing **Retrobulbar Neuritis**. It typically presents with a decrease in visual acuity and **red-green color blindness**, not a bull's eye macular pattern. **High-Yield Clinical Pearls for NEET-PG:** * **Early Screening:** The earliest sign of toxicity is a **paracentral scotoma** (detected via Humphrey Visual Field 10-2). * **Diagnosis:** **Optical Coherence Tomography (OCT)** shows the "Flying Saucer sign" (loss of outer retinal layers). **Fundus Autofluorescence (FAF)** is also highly sensitive. * **Other causes of Bull's Eye Maculopathy:** Stargardt’s disease, Cone-Dystrophy, and Benign Concentric Macular Dystrophy. * **Management:** Toxicity is irreversible; the drug must be discontinued immediately upon detection of early changes.

Q: Which local anesthetic is specifically used to produce corneal anesthesia for tonometry?

Benoxinate. **Explanation:** **Benoxinate (Oxybuprocaine)** is the drug of choice for corneal anesthesia during tonometry (specifically Goldmann Applanation Tonometry) because it provides rapid onset (within 30 seconds) and a brief duration of action. Crucially, it is highly compatible with **Fluorescein sodium**, often available in a premixed formulation (Fluress). Unlike other agents, it causes minimal stinging and has a lower risk of causing significant corneal epithelial toxicity or "pitting," which could interfere with accurate intraocular pressure (IOP) readings. **Analysis of Incorrect Options:** * **Tetracaine (Amethocaine):** While commonly used for minor ocular procedures and foreign body removal, it causes significant stinging/burning on instillation and is more toxic to the corneal epithelium compared to Benoxinate. * **Ropivacaine:** This is a long-acting amide anesthetic used primarily for regional anesthesia (e.g., peribulbar or retrobulbar blocks) in ocular surgeries, not for topical surface anesthesia. * **Oxethazaine:** This is a potent mucosal anesthetic used primarily in antacid suspensions for symptomatic relief of gastritis; it has no role in ophthalmic practice. **High-Yield Clinical Pearls for NEET-PG:** * **Proparacaine:** Another common topical anesthetic; it is preferred for pediatric patients because it causes the least amount of initial stinging. * **Mechanism:** Local anesthetics work by blocking **voltage-gated sodium channels**, preventing nerve depolarization. * **Warning:** Topical anesthetics should **never** be prescribed for home use or chronic pain relief, as they inhibit corneal healing and can lead to "Anesthetic Keratopathy" (permanent corneal melting and perforation). * **Preservative:** Most topical drops contain **Benzalkonium chloride (BAK)**, which can enhance drug penetration but may cause ocular surface irritation.

Q: Pilocarpine is an:

Active miotic. **Explanation:** **Pilocarpine** is a direct-acting parasympathomimetic (cholinergic) drug. It acts directly on the **muscarinic receptors (M3)** located on the **sphincter pupillae** muscle of the iris. 1. **Why it is an Active Miotic:** An "active" agent is one that causes contraction of a muscle to achieve its effect. Pilocarpine stimulates the sphincter pupillae to contract, leading to pupillary constriction (miosis). Because it achieves miosis through the active stimulation of a muscle, it is classified as an **Active Miotic**. 2. **Why other options are incorrect:** * **Passive Miotic:** This would involve the relaxation of the dilator pupillae muscle (e.g., via sympathetic blockers like Guanethidine). Pilocarpine does not work by relaxation; it works by contraction. * **Active Mydriatic:** These are drugs that cause pupillary dilation by actively contracting the dilator pupillae (e.g., Phenylephrine, an alpha-1 agonist). * **Passive Mydriatic:** These cause dilation by paralyzing/relaxing the sphincter pupillae (e.g., Atropine or Tropicamide, which are anticholinergics). **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism in Glaucoma:** Pilocarpine causes contraction of the **ciliary muscle**, which pulls on the scleral spur, opens the trabecular meshwork, and increases aqueous outflow. * **Drug of Choice:** It is the emergency drug of choice in **Acute Angle Closure Glaucoma** (used once intraocular pressure is lowered below 40 mmHg). * **Side Effects:** Brow ache (due to ciliary muscle spasm), induced myopia, and a potential risk of retinal detachment. * **Contraindication:** It should be avoided in young patients (due to accommodative spasm) and in cases of uveitic glaucoma (may promote posterior synechiae).

Q: Which antiglaucoma drug acts by increasing uveoscleral outflow?

Latanoprost. **Explanation:** The correct answer is **Latanoprost**. To understand why, we must look at how aqueous humor exits the eye. There are two main pathways: the **Trabecular (conventional) pathway** (80-90%) and the **Uveoscleral (unconventional) pathway** (10-20%). **1. Why Latanoprost is correct:** Latanoprost is a **Prostaglandin F2α analogue**. It works by remodeling the extracellular matrix in the ciliary muscle, reducing resistance and significantly increasing **uveoscleral outflow**. Due to their high efficacy and once-daily dosing, PG analogues are the first-line treatment for Primary Open Angle Glaucoma (POAG). **2. Why the other options are incorrect:** * **Apraclonidine:** An alpha-2 agonist. It primarily acts by **decreasing aqueous production** and, to a lesser extent, increasing trabecular outflow. * **Timolol:** A non-selective beta-blocker. It acts solely by **decreasing aqueous production** from the ciliary epithelium. It has no effect on outflow. * **Brinzolamide:** A topical Carbonic Anhydrase Inhibitor (CAI). It reduces the secretion of aqueous humor by inhibiting the enzyme required for bicarbonate production in the ciliary body. **High-Yield Clinical Pearls for NEET-PG:** * **Uveoscleral Outflow:** Increased by Prostaglandins (Latanoprost, Bimatoprost) and Alpha-agonists (Brimonidine). * **Trabecular Outflow:** Increased by Miotics (Pilocarpine) and Rho-kinase inhibitors (Netarsudil). * **Side Effects of Latanoprost:** Increased iris pigmentation (heterochromia), hypertrichosis (thickening of eyelashes), and cystoid macular edema (CME) in aphakic patients. * **Contraindication:** Avoid PG analogues in inflammatory glaucoma (uveitic glaucoma) as they may exacerbate inflammation.

Question 1

A patient with glaucoma is being treated with systemic beta blockers. Which of the following medications should be avoided?

Accepted Answer

Levobunolol

Answer

Brimonidine

Answer

Dorzolamide

Answer

Prostaglandin analogue

Question 2

Pilocarpine is not used in young adults as it causes:

Accepted Answer

Myopia

Answer

Retinal detachment

Answer

Iris cysts

Answer

Shallow anterior chamber

Question 3

Which of the following statements is NOT true regarding atropine?

Accepted Answer

Fast acting

Answer

Used as an eye ointment

Answer

Used in refraction in children less than 5 years old

Answer

Experimentally used in the treatment of myopia

Question 4

Which of the following clinical trials is used to measure the response of a drug in non-infectious uveitis?

Accepted Answer

Luminate

Answer

CATT

Answer

ETDRS

Answer

AREDS

Question 5

Which agent is used for pupillary dilatation in children?

Accepted Answer

Atropine

Answer

Homatropine

Answer

Tropicamide

Answer

Phenylephrine

Question 6

Which drug is known to cause bull's eye maculopathy?

Accepted Answer

Chloroquine

Answer

Phenytoin

Answer

Steroids

Answer

Ethambutol

Question 7

Which local anesthetic is specifically used to produce corneal anesthesia for tonometry?

Accepted Answer

Benoxinate

Answer

Tetracaine

Answer

Ropivacaine

Answer

Oxethazaine

Question 8

Which of the following causes the least increase in intraocular pressure?

Accepted Answer

Flouromethalone

Answer

Triamcinolone

Answer

Dexamethasone

Answer

Hydrocortisone

Question 9

Pilocarpine is an:

Accepted Answer

Active miotic

Answer

Passive miotic

Answer

Active mydriatic

Answer

Passive mydriatic

Question 10

Which antiglaucoma drug acts by increasing uveoscleral outflow?

Accepted Answer

Latanoprost

Answer

Apraclonidine

Answer

Timolol

Answer

Brinzolamide

Ophthalmic Pharmacology — MCQs

Ophthalmic Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?